Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea

Clin Transl Radiat Oncol. 2023 Aug 30:43:100672. doi: 10.1016/j.ctro.2023.100672. eCollection 2023 Nov.

Sean M O'Cathail¹, Richard Adams², Maria A Hawkins³, David Sebag-Montefiore⁴, Corrie A M Marijnen^{5

6}, Emmanouil Fokas^{7

8

9

10}

¹ School of Cancer Sciences, University of Glasgow & Beatson Cancer Centre, Glasgow, UK.
² Velindre Cancer Centre, Cardiff, UK.
³ Department of Medical Physics and Bioengineering, University College London, UK.
⁴ Leeds Institute of Medical Research, University of Leeds, UK.
⁵ Dept of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, NL, Netherlands.
⁶ Dept of Radiation Oncology, Leiden University Medical Center, Leiden, NL, Leiden University Medical Center, Netherlands.
⁷ Department of Radiotherapy of Oncology, University of Frankfurt, Germany.
⁸ German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁹ German Cancer Consortium (DKTK), Partner Site: Frankfurt, Germany.
¹⁰ Frankfurt Cancer Institute (FCI), Germany.

No abstract available

Keywords: Chemotherapy; Guidelines; Overtreatment; PROSPECT; QoL; Radiotherapy; Rectal cancer; Trials.